15 December 2022 
EMA/CHMP/929228/2022  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Adcirca 
tadalafil 
On 15 December 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Adcirca. The marketing authorisation holder for this medicinal product is Eli Lilly Nederland B.V. 
The CHMP adopted a new indication for the treatment of patients aged 2 years and above with pulmonary 
arterial hypertension. For information, the full indication will be as follows:2 
Adults 
Treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and 
III, to improve exercise capacity (see section 5.1). 
Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular 
disease. 
Paediatric population 
Treatment of paediatric patients aged 2 years and above with pulmonary arterial 
hypertension (PAH) classified as WHO functional class II and III. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
